The Covid-19 vaccine manufacturer Novavax Inc is eyeing a go-ahead from the Indian regulators for permitting its vaccine for emergency use authorization or EUA. The American biotech company has a vaccine-producing agreement with Pune’s Serum Institute of India (SII), which also brings out the Covishield vaccine being administered in India. Besides India, the US vaccine maker has requested the Philippines and Indonesia to permit EUA of its Covid vaccine, Covovax.
The company had said in June that its vaccine showed around 90% effectiveness against symptomatic Covid-19 in a study of about 30,000 people in America and Mexico. Its vaccine also performed against Covid-19 variants going around in the countries at the time and its side effects were largely mild.